AIIMS Ethics Committee approves Covaxin trial against COVID-19

Date: 2020-07-20   Author: Saipriya Iyer  Category: #news

AIIMS Ethics Committee approves Covaxin trial against COVID-19

AIIMS Ethics Committee has recently approved the clinical trial of Covaxin, India’s indigenously developed vaccine in the fight against the COVID-19 disease. The premier hospital is expected to start enrolling patients or volunteers from 20th July.

The ICMR (Indian Council for Medical Research) has selected 12 sites including AIIMS-Delhi to commence the Phase I & II human trials of the COVID-19 vaccine candidate, Covaxin. In the Phase I trial, 375 volunteers will be enrolled, out of which, up to 100 participants are likely to be selected from AIIMS.

According to Dr. Sanjay Rai, Professor at AIIMS’s Centre for Community Medicine, healthy volunteers, with no comorbid health conditions or history of COVID-19, from 18-55 years of age are eligible to participate in the double-blind, randomized, placebo-controlled trial. Prior to vaccinating the participants, they will be screened to evaluate the health conditions. A few volunteers have registered for the recent Covaxin trial.

Dr. Rai has further stated that the Ethics Committee had previously raised some concerns on the protocols for conducting the clinical trial. After addressing those concerns, the EC has given the approval to commence the vaccine study by the premier institute.

The vaccine candidate, Covaxin, has been developed by Bharat Biotech based in Hyderabad, by collaborating with the NIV (National Institute of Virology) and the ICMR. Moreover, it has recently gained approval from the DCGI (Drugs Controller General of India) to start the human trials. The clinical trials have been started in Patna, AIIMS, and some other sites to date.

In addition to the recent vaccine, the DCGI has approved the vaccine developed by Zydas Cadila Healthcare to commence the Phase I and II trials.

General Director of ICMR, Dr. Balram Bhargava, has cited that these vaccine candidates have been studied in rabbits, rats, and mice. The data from these studies were later submitted to the DCGI. He further added that nearly 1,000 volunteers will participate in the trials of the recent vaccine candidates to fast-track vaccine development in India.

Source credit:

https://www.newindianexpress.com/nation/2020/jul/19/covid-19-aiims-ethics-committee-nod-to-human-clinical-trial-of-covaxin-2171849.html

 



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Antenatal Screening Market Share, By Product Analysis, Application, End-Use, Regional Outlook, Competitive Strategies & Forecast up to 2028

Author: Ashwin Naphade

Global Antenatal Screening Market, 2022-2028 Research Report provides crucial statistics on the market status of the Global Antenatal Screening manufacturers and is a respected source of guidance and direction for companies and individuals interes...


Pediatric Vitrectomy Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2028

Author: Ashwin Naphade

Global Pediatric Vitrectomy market report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The Pediatric Vitrectomy market repor...


Legionnaire Disease Testing Market Comprehensive Analysis, Share, Growth Forecast from 2022 to 2028c

Author: Ashwin Naphade

This report studies the Global Legionnaire Disease Testing market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, ...